Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)
Dr. Cauwenbergh's career has been focused in dermatology. Early in hiscareer he was the International Director of Clinical R&D, Dermatology andInfectious Diseases at the Janssen Research Foundation at JanssenPharmaceutica in Belgium. This was followed with executive roles at Johnson &Johnson (J&J) including VP Research & Development for J&J Consumer CompaniesWorldwide, VP Product Development, as well as serving on the J&J ConsumerCompany's Management Board and Director of J&J' s Corporate Skin Care Council.
Advertisement
In 2001 he founded Barrier Therapeutics with offices in the US andBelgium, raising over $250 million in venture capital as well as a listing onthe NASDAQ stock exchange. He developed a portfolio of dermatology products,taking the company to annual sales exceeding $45 million until it was recentlyacquired by Stiefel Laboratories, Inc.
In August Dr. Cauwenbergh took on the role of CEO of RHEI Pharmaceuticals,a specialty pharmaceutical company with operations in Belgium, the U.S. andChina. RHEI develops and commercializes pharmaceutical products for theChinese market. Dr. Cauwenbergh has authored over 100 publications andco-authored several books. He received his Ph.D. in Medical Sciences from theCatholic University of Leuven, Faculty of Medicine, in Belgium.
"We are very pleased to have Dr. Cauwenbergh on our international advisoryboard," said Mr. Terry Howlett, President and CEO of Skinvisible, Inc. "Hebrings an abundant amount of knowledge and experience that can assist us inimplementing an aggressive expansion strategy into international markets,particularly China and Europe."
"I am very pleased to be advising Skinvisible on their internationalefforts," said Dr. Cauwenbergh. "High development costs coupled with theextensive time required to get new products to market is almost prohibitivetoday. Many pharmaceutical companies are looking at ways to offer Life CycleManagement to their existing portfolio, particularly companies with productscoming off patent. Skinvisible offers these companies the opportunity todevelop new products by combining their existing active ingredients with theInvisicare polymer delivery system which offers new innovative benefits like acontrolled release, superior adherence and most importantly, an opportunityfor a new patent -- benefits the generic competitors cannot offer."
About Invisicare(R)
Invisicare is Skinvisible's patented polymer delivery system that offerslife-cycle management and unique enhancements for topically deliveredproducts. It is a combination of hydrophilic and hydrophobic polymers thathold active ingredients on the skin for extended periods of time resistingboth wash off and perspiration. Invisicare can control the release ofactives, reduce irritation and can eliminate some costly manufacturingprocesses. It is non-occlusive and allows for normal skin respiration whileprotecting against environmental irritants. http://www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whoseprimary business objective is to license its proprietary formulations withInvisicare to pharmaceutical and cosmeceutical companies as well as assistingcompanies in enhancing their existing skin care products. Skinvisible receivesa combination of research and development fees, upfront license fees, andongoing royalties for the life of the Invisicare patent. Skinvisible's valuealso lies in its ability to continually generate new IP on dermatology andmedical products formulated with Invisicare. http://www.skinvisible.com
Forward-Looking Statements: This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, asamended, and Section 21E of the Securities Exchange Act of 1934, as amended,and are subject to the safe harbors created thereby. Such statements involvecertain risks and uncertainties associated with an emerging company. Actualresults could differ materially from those projected in the forward lookingstatements as a result of risk factors discussed in Skinvisible, Inc. reportson file with the U.S. Securities and Exchange Commission (including, but notlimited to, a report on Form 10Q for the quarter ending June 30, 2008)Corporate Contact: Terry Howlett, President/CEO Skinvisible Pharmaceuticals, Inc. Phone: 702-433-7154 Email: [email protected]
SOURCE Skinvisible, Inc.
